• About
    • Overview
    • Leadership
    • Board of Directors
  • Products
    • SYMJEPI® (epinephrine)
    • ZIMHI® (naloxone)
  • Pipeline
  • Patients
  • Investors & Media
  • Partnerships
  • Contact Us
Menu
  • About
    • Overview
    • Leadership
    • Board of Directors
  • Products
    • SYMJEPI® (epinephrine)
    • ZIMHI® (naloxone)
  • Pipeline
  • Patients
  • Investors & Media
  • Partnerships
  • Contact Us

Author: Gaurav

Pittsburgh Post-Gazette (7/9/19): Alternative to EpiPen hits the market

Allergic Living (7/9/19): Symjepi Epinephrine Syringe Rolls Out, as Mylan Shortage Persists

Pharmaceutical Manufacturing (7/10/19): Novartis puts generic epinephrine shots up for sale in US

Kids With Food Allergies (7/10/19): What are your options for injectable epinephrine devices?

Snack Safely (7/10/19): Watch: How to Use Symjepi, the Prefilled Epinephrine Syringe Now Available in Pharmacies

Monthly Prescribing Reference (7/10/19): Symjepi 0.15mg, 0.3mg Injections Now Available for Anaphylaxis Treatment

Generics Bulletin (7/10/19): Sandoz Seeks Help From Doctors For US Symjepi Push

SF Gate (7/10/19): “There’s Nothing to Give Them”: The Hunt for Lifesaving Epipens

BioPharma Dive (7/10/19): Sandoz widens launch of EpiPen rival as shortage continues

← older
newer →

Sign Up For Adamis Pharmaceuticals Email Alerts

Choose Your Preferences

Adamis Pharmaceuticals is a clinical stage neuro-biotechnology company focused on the development and commercialization of potential blockbuster products for the treatment of a variety of neuro-based disorders with significant unmet medical needs.

Linkedin Twitter

COMPANY

  • About Us
  • Overview
  • Leadership
  • Board of Directors

PRODUCTS

  • SYMJEPI® (epinephrine)
  • ZIMHI® (naloxone)

PIPELINE

  • New Molecular Entities

INVESTORS & MEDIA

  • Overview
  • News & Releases
  • Stock Information
  • SEC Filings
  • Events and Presentations
  • Corporate Governance
  • Email Alerts

CONNECT

  • Partnerships
  • Contact Us

© 2023 Copyright Adamis Pharmaceuticals

  • Terms and Conditions
  • Privacy Policy
Adamis Pharmaceuticals logo

ADAMIS Announces Merger With DMK Pharmaceuticals

What is DMK?
Private, clinical-stage, neuro-biotech company
  • Focused on developing potential blockbuster products for underserved patients.
  • Product candidates selected and developed from proprietary library of approximately 750 small molecule neuropeptide analogues with broad utility.

Developing multiple first-in-class products targeting large unmet needs
  • Addiction
  • Acute and chronic pain
  • Parkinson’s disease
  • Bladder control
  • Other neuro-based diseases

Want to learn more?

Read our press release go to our Investor Relations page or visit https://dmkpharma.com/

Check this page for the most recent updates regarding the merger process.